Currax Drug Patent Portfolio
Currax owns 3 orange book drugs protected by 54 US patents Given below is the list of Currax's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10076614 | Nasal delivery devices | 20 Oct, 2034 | Active |
| US10478574 | Nasal administration | 04 Nov, 2033 | Active |
| US8978647 | Nasal delivery | 06 Dec, 2030 | Active |
| US9649456 | Nasal administration | 21 Oct, 2030 | Active |
| US8513299 | Methods of using low-dose doxepin for the improvement of sleep | 07 Sep, 2030 | Active |
| US8899229 | Powder delivery devices | 18 Aug, 2030 | Active |
| US8550073 | Nasal delivery | 22 Oct, 2029 | Active |
| US10076615 | Nasal delivery | 30 Jul, 2029 | Active |
| US9532971 | Low-dose doxepin formulations and methods of making and using the same | 01 Jun, 2029 | Active |
| US10722667 | Nasal administration | 30 Dec, 2028 | Active |
| US9107898 | Methods of using low-dose doxepin for the improvement of sleep | 01 May, 2028 | Active |
| US10548871 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US11096920 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US9907780 | Low-dose doxepin formulations and methods of making and using the same | 11 Apr, 2028 | Active |
| US8875704 | Nasal administration | 07 Apr, 2028 | Active |
| US11234954 | Low-dose doxepin for treatment of sleep disorders in elderly patients | 18 Jan, 2028 | Active |
| US10398859 | Nasal delivery devices | 19 Dec, 2027 | Active |
| US7915307 | Methods of improving the pharmacokinetics of doxepin | 24 Aug, 2027 | Active |
| US10653660 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US11110074 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US9572814 | Methods of improving the pharmacokinetics of doxepin | 20 Jul, 2027 | Active |
| US10238620 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US10653662 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US12083090 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US9486437 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US9861607 | Methods of using low-dose doxepin for the improvement of sleep | 18 May, 2027 | Active |
| US10124132 | Nasal delivery | 06 Mar, 2027 | Active |
| US7332183 | Multilayer dosage forms containing NSAIDs and triptans | 02 Apr, 2026 | Active |
| US11571531 | Powder delivery devices | 23 Feb, 2026 | Active |
| US7332183 | Multilayer dosage forms containing NSAIDs and triptans | 02 Oct, 2025 | Active |
| US8590530 | Nasal delivery devices | 15 Sep, 2025 | Active |
| US9108015 | Nasal delivery devices | 15 Sep, 2025 | Active |
| US7975690 | Nasal devices | 18 Aug, 2025 | Active |
| US9119932 | Nasal delivery device | 23 Apr, 2024 | Expired |
| US8327844 | Nasal delivery method | 03 Oct, 2023 | Expired |
| US8047202 | Nasal devices | 02 Jul, 2023 | Expired |
| US6715485 | Nasal delivery device | 03 Mar, 2020 | Expired |
| US8555877 | Nasal delivery device | 03 Mar, 2020 | Expired |
| US6211229 | Treatment of transient and short term insomnia | 17 Feb, 2020 | Expired |
| US5872145 | Formulation of 5-HT agonist and NSAID for treatment of migraine | 14 Feb, 2018 | Expired |
| US6060499 | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs | 14 Feb, 2018 | Expired |
| US6586458 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs | 14 Feb, 2018 | Expired |
| US8022095 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs | 14 Feb, 2018 | Expired |
| US5872145 | Formulation of 5-HT agonist and NSAID for treatment of migraine | 14 Aug, 2017 | Expired |
| US6060499 | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs | 14 Aug, 2017 | Expired |
| US6586458 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs | 14 Aug, 2017 | Expired |
| US8022095 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs | 14 Aug, 2017 | Expired |
| US5585115 | Pharmaceutical excipient having improved compressability | 09 Jan, 2015 | Expired |
| US5725884 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5866166 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5948438 | Pharmaceutical formulations having improved disintegration and/or absorptivity | 09 Jan, 2015 | Expired |
| US6103219 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US6217909 | Pharmaceutical excipient having improved compressibility | 09 Jan, 2015 | Expired |
| US5502047 | Treatment for insomnia | 26 Mar, 2013 | Expired |
Latest Legal Activities on Currax's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Currax.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 19 Jun, 2024 | US9532971 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Apr, 2024 | US9486437 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Jan, 2024 | US10722667 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Nov, 2023 | US10653662 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Nov, 2023 | US10653660 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Jul, 2023 | US10548871 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 May, 2023 | US10478574 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8047202 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 Feb, 2023 | US9119932 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10398859 |
|
Recordation of Patent Grant Mailed
Critical
| 07 Feb, 2023 | US11571531 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 07 Feb, 2023 | US11571531 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Feb, 2023 | US9108015 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Feb, 2023 | US9107898 |
|
Email Notification
Critical
| 19 Jan, 2023 | US11571531 |
Currax's Drug Patent Litigations
Currax's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 08, 2011, against patent number US8513299. The petitioner , challenged the validity of this patent, with Roberta L. Rogowski et al as the respondent. Click below to track the latest information on how companies are challenging Currax's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7332183 | November, 2015 |
Terminated-Denied
(06 May, 2016)
| POZEN Inc. | Graybar Pharmaceuticals, LLC |
| US8513299 | August, 2011 |
Decision
(07 Dec, 2012)
| Roberta L. Rogowski et al | |
Currax Drug Patents' Oppositions Filed in EPO
Currax drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 27, 2005, by Direct-Haler A/S. This opposition was filed on patent number EP00906570A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP08736896A | Jun, 2021 | Beck Greener LLP | Patent maintained as amended |
| EP13715145A | Sep, 2020 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP00906570A | Sep, 2005 | Direct-Haler A/S | Opposition rejected |
Currax's Family Patents
Currax drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 33.4% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Currax Drug List
Given below is the complete list of Currax's drugs and the patents protecting them.
1. Onzetra Xsail
Onzetra Xsail is protected by 20 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10076614 | Nasal delivery devices |
20 Oct, 2034
(9 years from now)
| Active |
| US10478574 | Nasal administration |
04 Nov, 2033
(8 years from now)
| Active |
| US8978647 | Nasal delivery |
06 Dec, 2030
(5 years from now)
| Active |
| US9649456 | Nasal administration |
21 Oct, 2030
(5 years from now)
| Active |
| US8899229 | Powder delivery devices |
18 Aug, 2030
(5 years from now)
| Active |
| US8550073 | Nasal delivery |
22 Oct, 2029
(4 years from now)
| Active |
| US10076615 | Nasal delivery |
30 Jul, 2029
(4 years from now)
| Active |
| US10722667 | Nasal administration |
30 Dec, 2028
(4 years from now)
| Active |
| US8875704 | Nasal administration |
07 Apr, 2028
(3 years from now)
| Active |
| US10398859 | Nasal delivery devices |
19 Dec, 2027
(3 years from now)
| Active |
| US10124132 | Nasal delivery |
06 Mar, 2027
(2 years from now)
| Active |
| US11571531 | Powder delivery devices |
23 Feb, 2026
(1 year, 2 months from now)
| Active |
| US8590530 | Nasal delivery devices |
15 Sep, 2025
(8 months from now)
| Active |
| US9108015 | Nasal delivery devices |
15 Sep, 2025
(8 months from now)
| Active |
| US7975690 | Nasal devices |
18 Aug, 2025
(7 months from now)
| Active |
| US9119932 | Nasal delivery device |
23 Apr, 2024
(7 months ago)
| Expired |
| US8327844 | Nasal delivery method |
03 Oct, 2023
(1 year, 2 months ago)
| Expired |
| US8047202 | Nasal devices |
02 Jul, 2023
(1 year, 5 months ago)
| Expired |
| US6715485 | Nasal delivery device |
03 Mar, 2020
(4 years ago)
| Expired |
| US8555877 | Nasal delivery device |
03 Mar, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onzetra Xsail's drug page
2. Silenor
Silenor is protected by 24 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8513299 | Methods of using low-dose doxepin for the improvement of sleep |
07 Sep, 2030
(5 years from now)
| Active |
| US9532971 | Low-dose doxepin formulations and methods of making and using the same |
01 Jun, 2029
(4 years from now)
| Active |
| US9107898 | Methods of using low-dose doxepin for the improvement of sleep |
01 May, 2028
(3 years from now)
| Active |
| US10548871 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(3 years from now)
| Active |
| US11096920 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(3 years from now)
| Active |
| US9907780 | Low-dose doxepin formulations and methods of making and using the same |
11 Apr, 2028
(3 years from now)
| Active |
| US11234954 | Low-dose doxepin for treatment of sleep disorders in elderly patients |
18 Jan, 2028
(3 years from now)
| Active |
| US7915307 | Methods of improving the pharmacokinetics of doxepin |
24 Aug, 2027
(2 years from now)
| Active |
| US10653660 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(2 years from now)
| Active |
| US11110074 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(2 years from now)
| Active |
| US9572814 | Methods of improving the pharmacokinetics of doxepin |
20 Jul, 2027
(2 years from now)
| Active |
| US10238620 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(2 years from now)
| Active |
| US10653662 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(2 years from now)
| Active |
| US12083090 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(2 years from now)
| Active |
| US9486437 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(2 years from now)
| Active |
| US9861607 | Methods of using low-dose doxepin for the improvement of sleep |
18 May, 2027
(2 years from now)
| Active |
| US6211229 | Treatment of transient and short term insomnia |
17 Feb, 2020
(4 years ago)
| Expired |
| US5585115 | Pharmaceutical excipient having improved compressability |
09 Jan, 2015
(9 years ago)
| Expired |
| US5725884 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(9 years ago)
| Expired |
| US5866166 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(9 years ago)
| Expired |
| US5948438 | Pharmaceutical formulations having improved disintegration and/or absorptivity |
09 Jan, 2015
(9 years ago)
| Expired |
| US6103219 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(9 years ago)
| Expired |
| US6217909 | Pharmaceutical excipient having improved compressibility |
09 Jan, 2015
(9 years ago)
| Expired |
| US5502047 | Treatment for insomnia |
26 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Silenor's drug page
3. Treximet
Treximet is protected by 10 patents, out of which 8 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7332183
(Pediatric)
| Multilayer dosage forms containing NSAIDs and triptans |
02 Apr, 2026
(1 year, 3 months from now)
| Active |
| US7332183 | Multilayer dosage forms containing NSAIDs and triptans |
02 Oct, 2025
(9 months from now)
| Active |
| US5872145
(Pediatric)
| Formulation of 5-HT agonist and NSAID for treatment of migraine |
14 Feb, 2018
(6 years ago)
| Expired |
| US6060499
(Pediatric)
| Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
14 Feb, 2018
(6 years ago)
| Expired |
| US6586458
(Pediatric)
| Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
14 Feb, 2018
(6 years ago)
| Expired |
| US8022095
(Pediatric)
| Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
14 Feb, 2018
(6 years ago)
| Expired |
| US5872145 | Formulation of 5-HT agonist and NSAID for treatment of migraine |
14 Aug, 2017
(7 years ago)
| Expired |
| US6060499 | Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs |
14 Aug, 2017
(7 years ago)
| Expired |
| US6586458 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
14 Aug, 2017
(7 years ago)
| Expired |
| US8022095 | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
14 Aug, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Treximet's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List